top of page
美国二诊

​5天视频咨询美国前三医院顶级名医

VIDEO CONSULT A TOP US SPECIALIST

感恩8年信任,我们服务了数千亚洲家庭
一键连线72专科全美Top1%医院医生网络

Brush Stroke_edited.png

见诸权威媒体

AS SEEN IN

​美 联 医 邦 Medebound HEALTH

福布斯.png
startuphealth.png
中国经济周刊.png
公关网.png
businessinsider.png
IMECC.png
MedSci.png
网易财经.png
医道云.png

谁适合视频美国
前三医院专家

WHY YOU SHOULD CHOOSE 2ND OPINION

Brush Stroke_edited.png

温馨提示:如果您有可能比较严重的疾病,且属于以下3种情况,您都应该认真考虑​寻求全美Top排名前三医院的权威专家的帮助。

Wheelchair Athlete

好的医生鼓励多寻求第二意见

​不好的医生却会给你压力马上治疗

为什么要寻求名医帮助:
治疗水平差异显著

MEDICAL DISCREPANCY EXISTS

医疗水平的差异:体现在国家和国家之间,也体现在地方医院和顶级医院之间,以及普通医生和顶级专家之间。这种差距带来了治疗效果的大相径庭。

中美癌症生存率对比

 美国著名安德森癌症中心,是美国癌症治疗中的权威机构,近15年来有11年在癌症领域排名第一,大部分癌症的5年生存率达80%以上。

中美癌症药物的差距

最新数据显示,美国在研新药数量约占全球的48.7%,全球一半的新药几乎都在美国; 排在第二和第三的英国、日本,占比仅有8.0%、7.0%;中国为4.1%。碾压式的优势,让美国新药、新疗法在数量和前沿上领跑全球。

33.png
CC.png

远程视频成功案例

SUCCESS STORIES 2ND OPINION

​美 联 医 邦 Medebound HEALTH

成立8年来,我们积累了数千海外专家远程咨询案例,科室覆盖从肿瘤癌症,到心血管神经疾病,到罕见疑难疾病,到小儿疾病,我们实现了72个专科覆盖

 案 例 

安德森顶级专家视频卵巢患者

患者林女士通过美联医邦成功获得了来自美国安德森癌症中心的治愈性治疗方案,其中包括干细胞移植,治愈率高达30%-50%。

22.png

 案 例 

安德森胰腺癌会诊案例:美国新药点燃胰腺癌患者希望

国内胰腺癌患者经视频会诊获安德森专家建议及特定抑制剂,美联医邦协助获取并支持美国靶向新药KRASTI的申请和国内使用,患者病情得到了持续缓解。

33.png

 案 例 

纪念斯隆MSKCC乳腺主席视频国内患者指明后续方案

乳腺癌晚期患者与MSKCC乳腺癌主任Dr. Norton线上咨询,疑假性绝经,调整用药,中山大学肿瘤中心按其方案执行,会诊意见落地。

11.png

 案 例 

哈佛丹娜法伯主任视频会诊26岁脑胶质瘤指出新方向

哈佛教授建议患者在美或德做全基因组检测甲基化分析,提供德国cegat个性化定制疫苗建议,患者家人赴海外治疗获希望。

44.png

远程二诊和落地流程

SUCCESS STORIES 2ND OPINION

 您只需要病历给我们,其他都由我们来完成。不需等待数个月预约面诊,1周内就可在家咨询全美前三医院Top专科专家。  

1.

发出申请表,提交病历

2.

我们专业水准的翻译病历和匹配美国专家

3.

5天视频美国Top专家,我们提供医学专业现场翻译

4.

​会诊后免费申请美国医院,或者全球找药协助患者自购当地治疗

视频+美国看病患者好评 

PATIENTS TESTIMONIALS SUCCESS STORIES  

C2-t.png
"沟通顺畅,业务知识扎实。起初抱着试一试的心态,​争取一个安德森的机会...最终在我顾问Jason的帮助下完美实现了我们想要的效果。"

王女士. 卵巢患者家属

"谢谢美联医邦,感谢你们帮我联系了多个美国顶级医院进行比价...我们落地美国后,你们贴心地给我们安排了陪诊人员...陪我们去买菜,购物,逛公园等等,衣食住行都替我们考虑得十分周到,完全像是家人一般的存在,非常温暖贴心。"

1岁SMA患儿家属

1岁SMA患儿.png

为什么选择我们 

WHY YOU SHOULD CHOOSE MEDEBOUND

独一无二的
Top美国名医资源

1000+ US Physician Network

不论是去美国看病还是美国专家远程会诊,对接到海外著名医院里面的TOP权威医生是其中至关重要的一步。卡思克鲁力是美国权威医生的最高奖项之一,联合创始人卡思先生和克鲁力博士是美联医邦的投资股东。 不同于其他中间商,我们覆盖美国上千家医院,72个专科的前1%和前5%的顶级医生的直通资源。

Brush Stroke_edited.png
Brush Stroke_edited.png
Girl at the Pediatrician
Patient with Healthcare Nurse

Endorsed by Largest Insurers

中国保险巨头背书

作为美国本土医疗资源的机构,且接受美国Forbe报道,至今美联医邦 Medebound HEALTH 已经在总对总层面,签约中国保险集团包括中国平安,泰康人寿,太平人寿等,服务覆盖数百万保险人群提供海外第二诊疗意见,出国看病和海外就医等海外看病医疗服务。

Brush Stroke_edited.png
Brush Stroke_edited.png

​8年我们只专注一件事

We Only Focus on One Thing

因专注而专业,WE TRULY CARE.

我们不止于海外二诊,更不遗余力为您找到海外最佳治疗手段。我们

专注落地解决方案, 协助方案在国内落地包括海外新药申请, 或协助赴美看病。

Brush Stroke_edited.png
Brush Stroke_edited.png
Eye Checkup
Holding Hands

常见问题

FREQUENTLY ASKED QUESTIONS
open Dev-Mode and select the section and click collapse

  • What is a Tech-Enabled Named Patient Program?
    In cases where biopharmaceutical companies lack the bandwidth or expertise to get their innovative medicines approved in other countries, a Named Patient Program can make their medicines available internationally. This process, a widely accepted practice for many pharmaceutical companies, enables healthcare professionals across the world to request new medicines, for patients who have no other treatment options available to them in their own countries. As part of the Personal Importation Process, the patient submits all the necessary documentation, including passport and medical information, to make a request for a small amount of medicine. We refer to our "Access as Services" program as "Tech-enabled Named Patient Program," and that means we not only handle the logistics of international shipment, custom clearance, storage and distribution, but also assist pharmaceutical companies in gaining market access that will generate early revenue for them, as well as provide them with the real-world evidence (RWE) necessary for local regulatory approval.
  • What are the advantages for companies of conducting a Named Patient Program in Asia?
    There are many advantages for biopharma companies with a newly approved medicine to discuss with us to set up a Named Patient Program: - Managing unsolicited patient requests for drugs in an ethical and regulatory controlled manner - Building a stronger network of KOLs and future advocates by exposing physicians in new markets to your products - Providing benefits to patients suffering from conditions, including some that can be life-threatening. - Generating additional revenues in countries that allow you to charge for drugs supplied on a named patient basis - RWE acquisition based on Asian demographics which accounts for 25% of the world population
  • Can pharmaceutical companies provide drug to patients in any country?
    Companies can provide drugs to patients in any country in which they have not yet received marketing authorization. This includes countries in which a company plans to seek marketing approval, as well as those countries in which a company does not plan to seek marketing approval. With a properly established Named Patient program, we help navigate the complex regulatory landscape, especially in Asia countries, and manage the shipment, customs clearance, and delivery to treating clinics. Asia is a huge, rapidly growing and attractive market that is hard to ignore. Building a reputable early entry program with a US-based partner with a significant local presence is essential. We invite biotech and biopharma companies interested in helping more patients who have no access to your medicines, to contact us.
  • How can I introduce Medebound HEALTH to a biopharma company?
    We can share introduction materials or schedule a demo to learn more about our full range of offerings.
  • Why choose Medebound HEALTH to be your partner in Asia?
    With access to our in-house expertise and knowledge of international regulatory and legal frameworks in Asia, we will be able to help pharmaceutical companies gain market access which will not only generate early revenue for them but also provide them with real-world evidence (RWE) crucial to local regulatory approval. In addition to relationships with top hospitals, KOLs and Government agencies, Medebound HEALTH also partners with largest rare disease consortium, and this year, signed an agreement to help their hundreds of thousands rare disease patients source the latest medicines –both approved and not-yet-approved. In the past, we have successfully imported and supplied of unlicensed medicines in oncology, neurology and rare diseases into the Asian region. Please contact us to learn more. Medebound HEALTH has established its brand presence in Asia by contracting with the Asia’s largest insurance firms, and global Fortune 500 companies. Its services have covered worldwide members touching millions of lives, bringing new hope to patients who would otherwise have to travel abroad for care.

我们不仅二诊,更专注帮您衔接先进方案下步落地办法

不论后续选择美国前三医院治疗,还是当地/本国治疗,美联医邦都会不遗余力地帮您寻求美国先进手段和定制化方案, 并协助您在本国或美国成功落地方案。

NYC Skyline BW

500强总部签约合作

SIGNED FORTUNE 500 BUSINESSES AND COLLABORATORS

image.png

​兴业银行私人银行

image.png

平安健康

image.png

太平人寿

image.png

招商银行和泰康人寿

image.png

​其他总对总签约合作机构:中宏人寿,中国人民保险,安盛救援,众安保险,招商信诺

Medebound-US.jpeg

纽约医学院前院长,哥伦比亚大学博士克鲁力博士 (Dr.Connolly) ,纽约五所医院包括纽约最大医院NYP长老会医院董事卡思先生 (Mr.Castle), 和哥伦比亚大学医学院博士(Dr.Liu) 共同在纽约组建美联医邦Medebound HEALTH.

关于我们

​ABOUT US

美国美联医邦Medebound HEALTH 是一家创始在美国,总部位于纽约,并在大陆和香港设有分部的国际医疗公司。

我们致力于帮助世界有疑难重疾患者对接到美国顶级医疗资源,专注于开展美国肿瘤罕见病名医的第二诊疗意见,视频咨询,出国就医和美国最新药物申请。至今美联医邦已经签约中国保险集团总部包括中国平安,泰康,太平人寿等,服务覆盖数百万保险人群。

提交申请

提交预约信息,我们将在8小时内联系您

感谢提交,我们会8小时内联系您


US Operation

260 Madison Ave 8th Floor #8001
New York, NY 10016

support@medebound.com
+1 718-213-8508

China Operation

 Click HERE

66 MiaoJing Rd. #K471

MingHang Dist, Shanghai
+86 400-616-2591

HongKong Operation 

Click HERE

Champiom Building #810A,
301-309 Nathan Rd,  HongKong
+852 53887561

bottom of page